Pirarubicin: Difference between revisions
Created page with "<div style="float: right;"> thumb|none|400px|This image is provided by the National Library of Medicine.</div> __NOTOC__ {{SI}} {{CMG}} ==Overview==..." |
No edit summary |
||
| Line 1: | Line 1: | ||
<div style="float: right;"> | <div style="float: right;"> | ||
[[File:Pirarubicin.png|thumb|none|400px|This image is provided by the National Library of Medicine.]]</div> | [[File:Pirarubicin.png|thumb|none|400px|This image is provided by the National Library of Medicine.]]</div> | ||
__NOTOC__ | __NOTOC__ | ||
{{SI}} | {{SI}} | ||
| Line 14: | Line 13: | ||
{{Chemotherapeutic agents}} | {{Chemotherapeutic agents}} | ||
[[Category:Anthracyclines]] | [[Category:Anthracyclines]] | ||
[[Category:Phenols]] | [[Category:Phenols]] | ||
[[Category:Phenol ethers]] | [[Category:Phenol ethers]] | ||
[[Category:Drug]] | [[Category:Drug]] | ||
Revision as of 13:08, 7 April 2015
|
WikiDoc Resources for Pirarubicin |
|
Articles |
|---|
|
Most recent articles on Pirarubicin Most cited articles on Pirarubicin |
|
Media |
|
Powerpoint slides on Pirarubicin |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Pirarubicin at Clinical Trials.gov Clinical Trials on Pirarubicin at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Pirarubicin
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Pirarubicin Discussion groups on Pirarubicin Patient Handouts on Pirarubicin Directions to Hospitals Treating Pirarubicin Risk calculators and risk factors for Pirarubicin
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Pirarubicin |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Pirarubicin (INN) is an anthracycline drug. An analogue of the anthracycline antineoplastic antibiotic doxorubicin. Pirarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent is less cardiotoxic than doxorubicin and exhibits activity against some doxorubicin-resistant cell lines.